SRR25617841
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.350
- KRAS_SIGNALING_DN+0.340
- MYOGENESIS+0.270
- PANCREAS_BETA_CELLS+0.240
- HYPOXIA+0.200
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.190
- GLYCOLYSIS+0.190
- SPERMATOGENESIS+0.180
- NOTCH_SIGNALING+0.160
- WNT_BETA_CATENIN_SIGNALING+0.130
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.520
- INTERFERON_GAMMA_RESPONSE-0.470
- PROTEIN_SECRETION-0.450
- COMPLEMENT-0.320
- ANDROGEN_RESPONSE-0.310
- ALLOGRAFT_REJECTION-0.280
- INFLAMMATORY_RESPONSE-0.270
- IL2_STAT5_SIGNALING-0.260
- IL6_JAK_STAT3_SIGNALING-0.260
- HEME_METABOLISM-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR25617838 | — | E | 0.834 |
| 2 | GSM6454752 | — | E | 0.816 |
| 3 | SRR1797259 | — | cohortSC | 0.798 |
| 4 | TCGA-AO-A0JL-01A-11R-A056-07 | — | E | 0.789 |
| 5 | TCGA-LL-A6FR-01A-12R-A31O-07 | — | E | 0.787 |
| 6 | SRR2016936 | — | — | 0.786 |
| 7 | TCGA-A2-A0CY-01A-12R-A034-07 | — | C | 0.781 |
| 8 | C3L-02163 | — | cohortSQ2 | 0.781 |
| 9 | TCGA-EW-A424-01A-11R-A24H-07 | — | B | 0.773 |
| 10 | MNG692 | — | — | 0.767 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.350 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.340 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.270 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.190 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.190 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.160 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.130 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.110 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.090 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.090 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.070 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.040 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.010 | Inavolisib | — uncovered |